GBG @ ESMO 2025 in Berlin!

This year as well, GBG presented the latest results from its clinical trials:

Mini oral presentation“Durvalumab in Combination with Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) – Long-term Analysis from the GeparNuevo Trial” presented by Sibylle Loibl

The long-term data clearly support the central message:

- After 7 years of follow-up, the addition of durvalumab to dose-dense neoadjuvant chemotherapy without carboplatin significantly improved iDFS, DDFS, and OS.

- The overall survival benefit is clinically highly relevant: 91.6% OS in the durvalumab arm versus 74.7% with placebo.

- The survival benefit was independent of achieving a pCR, indicating a durable immunologic effect.

- Patients with tumor-infiltrating lymphocytes (TILs) in residual disease showed excellent long-term outcomes, confirming the predictive value of tumor immunity.

➡️ GeparNuevo is therefore the only trial demonstrating a long-term survival benefit of a PD-L1 inhibitor in early TNBC, achieved without carboplatin and without adjuvant immunotherapy.

Poster presentation“HER2 IHC Status of Primary Breast Cancer Tumor and Brain Metastases in the BMBC Registry” presented by Elena Laakmann

Data from the BMBC registry (GBG79) show that HER2 status frequently changes between the primary tumor and brain metastases, with clear clinical relevance. Approximately 65% of patients with brain metastases exhibited HER2-low, ultralow, or HER2 3+ expression—a population that may potentially benefit from modern ADCs such as trastuzumab deruxtecan. In addition, HER2 status in brain metastases was associated with overall survival, supporting its role as a prognostic marker.

➡️ These data highlight the need to reassess HER2 status in metastatic lesions and open new targeted treatment opportunities, even for patients previously classified as HER2-negative.